Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: A phase II study

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 2, 2005, Pages 187-196

  Ferraresi, Virginia ^a   Giampaolo, M A ^b   Gabriele, A ^b   Mansueto, G ^b   Buccilli, A ^b   Giannarelli, D ^a   Ciccarese, M ^a   Gamucci, T ^b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Medical Oncology Unit   (Italy)

Author keywords

Advanced colorectal cancer; Bolus 5 fluorouracil; Chemotherapy; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG INFUSION; DRUG MEGADOSE; DYSESTHESIA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GROWTH REGULATION; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 22844432004     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Cunningham D., Findlay M.: The chemotherapy of colon cancer can no longer be ignored. Eur. J. Cancer 29A: 2077-2079, 1993.
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group: Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol. 10: 904-911, 1993.
3. Lokich J.J., Ahlgren J.D., Gullo J.J., Philips J.A., Fryer J.G.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma, a mid-Atlantic oncology program study. J. Clin. Oncol. 7: 425-432, 1989.
4. Sobrero A.F., Aschele C., Bertino J.R.: Fluorouracil in colorectal cancer - A tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 15: 368-381, 1997.
5. Raymond E., Buquet-Fagot C., Djelloul C.J. et al: Antitumoral activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anti-Cancer Drugs 8:876-885, 1997.
6. Raymond E., Lawrence R., Izbicka E., Faivre S., Von Hoff DD.: Activity of oxaliplatin against human tumor colony forming units. Clin. Cancer Res. 4(4): 1021-1029, 1998.
7. Raymond E., Chaney S.G., Taamma A., Cvitkovic E.: Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol. 9:1053-1071, 1998.
8. Gams R.A., Ramanathan R.K., Clark J., et al.: The oxaliplatin treatment access program: compassionate use experience of oxaliplatin as a single agent or in combination with 5-fluorouracil in more than 7000 patients with previously treated advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 22:1065, 2003.
9. Tournigand C., Louvet C., Quinaux E., et al.: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc. Am. Soc. Clin. Oncol. 20: 494, 2001.
10. Roca E., Montiel M., Barugel M., et al.: 5-Fluorouracil and leucovorin (MAYO regimen) plus bi-monthly oxaliplatin (OXA) in patients with advanced colorectal cancer (ACC). Proc. Am. Soc. Clin. Oncol. 18: 298a, 1999.
11. Sun Y., Guan Z.Z., Jin M.L., et al.: A multicenter randomized phase II trial of oxaliplatin alone and in combination in patients with advanced colorectal cancer in China. Proc. Am. Soc. Clin. Oncol. 18: 255a, 1999.
12. Marantz A., Lopez J., Ivulich C., et al.: First line chemotherapy with 5-fluorouracil (5FU), leucovorin (LV) and oxaliplatin (L-OHP) in metastatic colorectal cancer (MCC) patients (Pts). Proc. Am. Soc. Clin. Oncol. 19:271a, 2000.
13. Zori Comba A., Blajman C., Richardet E, et al.: A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur. J. Cancer 37: 1006-1013, 2001.
14. Ravaioli A., Marangolo M., Pasquini E., et al.: Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J. Clin. Oncol. 20: 2545-2550, 2002.
15. Tassinari D., Panzini I., Pasquini E., et al.: Oxaliplatin, 5FU and folinic acid (OFFA) as II line chemotherapy in advanced colorectal cancer. Eur. J. Cancer 35: 80, 1999.
16. Zaniboni A., Barni S., Aitini E., et al.: Oxaliplatin (OX) and weekly bolus 5-FU plus folinic acid (FA) as first-line treatment for advanced colorectal cancer (ACC). A G.I.S.C.A.D. study. Proc. Am. Soc. Clin. Oncol. 21: 136b, 2002.
17. Caussanel J.P., Levi F., Brienza S., et al.: Phase-I trial of five-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. 82: 1046-1050, 1990.
18. World Health Organization. Handbook for reporting results of cancer treatment. Pu. no. 48. Geneva: World Health Organization, 1979.
19. Simon R.: Optimal two stage designs for phase II clinical trials. Control Clin. Trial 10: 1-10, 1989.
20. Sobrero A.F., Aschele C., Guglielmi A.P., et al.: Schedule-selective biochemical modulation of 5-fluorouracil: phase II study in advanced colorectal cancer. Clin. Cancer Res. 1(9): 955-960, 1995.